Biolase, Inc.
BIOL
BIOL was delisted on the 18th of June, 2024.
31 hedge funds and large institutions have $37.4M invested in Biolase, Inc. in 2016 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 7 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
37% more capital invested
Capital invested by funds: $27.4M → $37.4M (+$10M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
11% less funds holding
Funds holding: 35 → 31 (-4)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
+$5.27M |
| 2 |
GIP
Granite Investment Partners
El Segundo,
California
|
+$765K |
| 3 |
CCM
Consonance Capital Management
New York
|
+$748K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$53.4K |
| 5 |
Renaissance Technologies
New York
|
+$53.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$6.24M |
| 2 |
PCMI
Princeton Capital Management Inc
Princeton,
New Jersey
|
-$196K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$53.4K |
| 4 |
SBIA
Sheaff Brock Investment Advisors
Indianapolis,
Indiana
|
-$33K |
| 5 |
BIP
Brandes Investment Partners
La Jolla,
California
|
-$27K |
BIOL Hedge Fund Activity: Q3 2016 in Review
31 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Biolase, Inc. (BIOL) for Q3 2016, worth a combined $37.4M — up 37% from $27.4M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of BIOL and 3 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 4 added.
The largest buyer was Oracle Investment Management, adding an estimated $5.27M. The largest seller was Camber Capital Management, exiting entirely with an estimated $6.24M sold.
- 31 institutional investors held Biolase, Inc. (BIOL) as of Q3 2016, down from 35 in Q2 2016.
- Funds reported $37.4M of Biolase, Inc. stock for Q3 2016, up 37% quarter-over-quarter.
- 3 funds opened new Biolase, Inc. positions in Q3 2016 and 7 closed out, a net change of -4 holders.
- The largest Biolase, Inc. buyer in Q3 2016 was Oracle Investment Management, an estimated $5.27M added.
- The largest Biolase, Inc. seller in Q3 2016 was Camber Capital Management, an estimated $6.24M sold.
Based on aggregated 13F filings for Q3 2016.